- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Biosergen AB: Nasdaq approves Biosergen's application for delisting from First North Growth Market conditional upon the Swedish Companies Registration Office granting permission to execute the merger with Flerie | 259 | GlobeNewswire (Europe) | Biosergen AB ("Biosergen" or the "Company") applied on 15 September 2026 for delisting of the Company's shares from Nasdaq First North Growth Market, in connection with the contemplated merger between... ► Artikel lesen | |
| 15.09. | Biosergen AB: Biosergen applies for delisting of the company's shares from Nasdaq First North Growth Market conditional upon completion of the merger with Flerie | 197 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB ("Biosergen" or the "Company") has today, on 15 September 2026, in connection with the contemplated merger between Biosergen and Flerie AB (publ) ("Flerie") (the... ► Artikel lesen | |
| 06.08. | Flerie AB: Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 6 August 2026 at 11:00 CEST | 182 | GlobeNewswire (Europe) | The extraordinary general meeting of Flerie AB (publ) reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 6 August 2026 at 11:00 CEST at which the following resolutions were made.
Resolution... ► Artikel lesen | |
| 30.07. | Flerie AB: Biotech-Investments mit deutlichem NAV-Discount | 518 | investresearch.net | Flerie AB ist eine schwedische Beteiligungsgesellschaft, die sich auf den Biotech- und Healthcare-Sektor spezialisiert hat. Für Investoren, die den anspruchsvollen und risikoreichen Bereich der Biotechnologie... ► Artikel lesen | |
| FLERIE Aktie jetzt für 0€ handeln | |||||
| 16.07. | BIOSERGEN AB: Flerie publishes merger document | 8 | Cision News | ||
| 09.07. | Flerie AB: Flerie AB (publ) Interim Report January - June 2026 | 309 | GlobeNewswire (Europe) | The period in brief• Net asset value was SEK 3,394 million (4,121) and net asset value per share was SEK 39.14 (52.78 on 30 June 2025). Change in net asset value per share in the quarter was -2.9 per... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 1.176 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 400 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | Flerie AB: Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm | 493 | GlobeNewswire (Europe) | Today, on 26 June 2026, Flerie AB (publ) ("Flerie") and Biosergen AB ("Biosergen") (together the "Companies") jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen... ► Artikel lesen | |
| 26.06. | Flerie AB: Flerie portfolio company Bonsai Biotherapeutics receives full approval of clinical trial application for TOL2 in myasthenia gravis | 434 | GlobeNewswire (Europe) | Flerie AB's portfolio company Bonsai Biotherapeutics has received full approval of its clinical trial application (CTA) for the drug candidate TOL2 for the treatment of AChR antibody-positive generalised... ► Artikel lesen | |
| 15.06. | Flerie AB: Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST | 204 | GlobeNewswire (Europe) | The extraordinary general meeting of Flerie AB (publ), reg. no. 559067-6820 ("Flerie" or the "Company") has been held on 15 June 2026 at 10:00 CEST at which the following main resolutions were made.
Resolution... ► Artikel lesen | |
| 14.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.05.2026 | 822 | Xetra Newsboard | Das Instrument MD9 JP3879400004 MANDOM CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 14.05.2026 und ex Kapitalmassnahme am 15.05.2026 The instrument MD9 JP3879400004 MANDOM CORP. EQUITY is traded... ► Artikel lesen | |
| 11.05. | Flerie AB: Flerie's majority owner waives share allocation - other owners' stake in the company increases by approximately 15.5 per cent | 294 | GlobeNewswire (Europe) | In connection with the termination of Flerie's redemption scheme, the Annual General Meeting resolved to carry out a bonus issue. The company's largest shareholder, Thomas Eldered, has undertaken to... ► Artikel lesen | |
| 15.04. | Flerie AB: Flerie AB (publ) Interim Report January - March 2026 | 255 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,670 million (3,947) and net asset value per share was SEK 41.90 (50.56 at 31 March 2025). Change in net asset value per share in the quarter was -3.9 per... ► Artikel lesen | |
| 26.03. | Flerie AB: Bulletin from the Annual General Meeting of Flerie AB (publ) on 26 March 2026 | 502 | GlobeNewswire (Europe) | The Annual General Meeting of Flerie AB (publ) reg. no. 559067-6820 (the "Company") has been held on 26 March 2026 and in particular the following resolutions were made.
Adoption of the annual report... ► Artikel lesen | |
| 20.03. | Flerie AB: The merger between Flerie and Lipum has been completed | 428 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 12.03. | Lipum AB: The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum | 353 | GlobeNewswire (Europe) | THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD... ► Artikel lesen | |
| 11.02. | Flerie AB: Flerie's portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis | 327 | GlobeNewswire (Europe) | Flerie AB's (publ) portfolio company Microbiotica has reported positive results from its Phase 1b first-in-human study of MB310 in patients with ulcerative colitis (UC). The positive data support Microbiotica's... ► Artikel lesen | |
| 02.02. | Flerie AB: Flerie's portfolio company Nanologica acquires Syntagon | 668 | GlobeNewswire (Europe) | Flerie AB (publ)'s portfolio company Nanologica has acquired Ardena Södertälje AB ('Syntagon'), a contract manufacturer with 45 employees. The acquisition strengthens Nanologica's production capacity... ► Artikel lesen | |
| 21.01. | Flerie AB: Flerie AB (publ) Year-end report 2025 | 270 | GlobeNewswire (Europe) | The period in briefNet asset value was SEK 3,377 million (4,198) and net asset value per share was SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MERCK KGAA | 135,00 | +0,78 % | Bio-Techne Shareholders Approve Merck KGaA Acquisition Plan | WASHINGTON (dpa-AFX) - Wednesday, Bio-Techne Corp. (TECH) announced that its shareholders have approved the acquisition of the company by Merck KGaA (MKKGY.PK), Darmstadt, Germany, marking an... ► Artikel lesen | |
| SANOFI | 71,89 | +0,01 % | Sanofi: Was die Millionen-Steuerforderung jetzt bedeutet | ||
| EYEPOINT | 3,180 | 0,00 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| PHOTOCURE | 4,590 | -1,50 % | Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II | OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed... ► Artikel lesen | |
| BAYER | 50,02 | +1,30 % | Aktie steigt: Bayer macht Kasse: Dieser Pharma-Deal bringt bis zu 375 Millionen Euro | © Foto: Juan Vega - EUROPA PRESSBayer verkauft Stivarga für bis zu 375 Millionen Euro an Grünenthal, stärkt damit seine Bilanz und treibt den Umbau der Pharmasparte weiter voran Enthaltene Werte: DE000BAY0017Den... ► Artikel lesen | |
| JAGUAR HEALTH | 7,620 | -1,04 % | Morning Market Movers: Wheeler REIT, Professional Diversity Network, Jaguar Health, Greenland Mines See Big Swings | BEIJING (dpa-AFX) - At 6:50 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 57,68 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| NOVO NORDISK | 33,890 | +0,62 % | Kapitalmarkttag in London: 70 Prozent unter dem Hoch: Auch Pillenpläne beruhigen Novo-Investoren nicht | © Foto: Christian Schultz/dpaNovo Nordisk will bis 2030 mehr als fünf Blockbuster liefern und setzt stark auf Abnehm-Tabletten. Die Anleger bleiben dennoch skeptisch, die Aktie verliert am Montag rund... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 21,520 | 0,00 % | Raymond James startet Coverage für Seaport Therapeutics mit "Strong Buy" - Potenzial bei Depressionsmedikament | ||
| SCHOTT PHARMA | 24,650 | +0,20 % | Schott Pharma: Was JPMorgans Kaufvotum jetzt auslöst | ||
| GENERATE BIOMEDICINES | 15,160 | 0,00 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| PFIZER | 25,150 | -0,10 % | Eli Lilly und Novo Nordisk bekommen neue Konkurrenz - warum der 100-Milliarden-Dollar-Markt immer mehr Biotech-Unternehmen anzieht | ||
| AQUESTIVE THERAPEUTICS | 4,675 | -0,11 % | Aquestive Therapeutics, Inc. - 8-K, Current Report | ||
| LB PHARMACEUTICALS | 37,330 | 0,00 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| GILEAD SCIENCES | 131,18 | -0,94 % | Gilead Sciences und Assembly Bio: Kommt am 13. Oktober der Herpes-Paukenschlag? | Bei Gilead Sciences verdichten sich derzeit die Hinweise darauf, dass der Pharmakonzern in den kommenden Jahren das Therapiefeld der Virologie massiv ausbauen und damit die langfristige Abhängigkeit... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLERIE AB finden Sie auf Wallstreet Online.